• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞戈非尼用于智利化疗耐药转移性结直肠癌患者的调整剂量：病例系列

Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.

作者信息

Leal José Luis, Briones Juan, Herrera María Elisa, Müller Bettina, Nervi Bruno, Mondaca Sebastián

机构信息

Medical Oncology Responsability Centre, Instituto Nacional del Cáncer, Santiago 8380455, Chile.

Medical Oncology Service, Instituto Oncológico Fundación Arturo López Pérez, Santiago 7501066, Chile.

出版信息

Ecancermedicalscience. 2018 Oct 2;12:875. doi: 10.3332/ecancer.2018.875. eCollection 2018.

DOI:10.3332/ecancer.2018.875
PMID:30483355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6214673/
Abstract

BACKGROUND

Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free survival (PFS) and quality of life (QoL) in a prospective cohort of Latin American patients treated with an adjusted dose of regorafenib.

METHODS

We prospectively recruited patients with MCRC that progressed to standard therapy. A dose escalation algorithm was used. OS, PFS, response rate and QoL were evaluated.

RESULTS

We recruited 13 patients between June and November 2015. The median age was 60 years. Median OS was 8.6 months and median PFS was 2.2 months. The response rate was 8%. Grade 3-4 toxicities included grade 3 palmoplantar erythrodysesthesia in 23% and grade 3 fatigue in 12% of patients.

CONCLUSION

Regorafenib treatment is effective in Latin American patients with conventional therapy resistant MCRC.

摘要

背景

瑞戈非尼是对传统疗法耐药的转移性结直肠癌（MCRC）患者的一种治疗选择。报道的毒性较为显著，且尚无关于拉丁美洲患者的数据。目的是评估接受调整剂量瑞戈非尼治疗的拉丁美洲患者前瞻性队列中的总生存期（OS）、无进展生存期（PFS）和生活质量（QoL）。

方法

我们前瞻性招募了对标准疗法进展的MCRC患者。使用了剂量递增算法。评估了OS、PFS、缓解率和QoL。

结果

我们在2015年6月至11月期间招募了13名患者。中位年龄为60岁。中位OS为8.6个月，中位PFS为2.2个月。缓解率为8%。3-4级毒性包括23%的患者出现3级掌跖红斑感觉异常和12%的患者出现3级疲劳。

结论

瑞戈非尼治疗对传统疗法耐药的拉丁美洲MCRC患者有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7400/6214673/16aae1ea22f3/can-12-875fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7400/6214673/16aae1ea22f3/can-12-875fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7400/6214673/16aae1ea22f3/can-12-875fig1.jpg

相似文献

1
Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.瑞戈非尼用于智利化疗耐药转移性结直肠癌患者的调整剂量：病例系列
Ecancermedicalscience. 2018 Oct 2;12:875. doi: 10.3332/ecancer.2018.875. eCollection 2018.
2
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.二线化疗失败后 ≥ 75 岁转移性结直肠癌（mCRC）患者采用 2/1 方案应用regorafenib 的疗效和安全性。
Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21.
3
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.regorafenib 在抗血管生成初治和化疗耐药的晚期结直肠癌患者中的疗效：一项 IIb 期试验的结果。
Oncologist. 2019 Sep;24(9):1180-1187. doi: 10.1634/theoncologist.2019-0067. Epub 2019 Jun 7.
4
Efficacy and safety of raltitrexed plus S-1 regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study.雷替曲塞联合S-1与瑞戈非尼治疗难治性转移性结直肠癌的疗效与安全性：一项真实世界倾向评分匹配研究
Therap Adv Gastroenterol. 2022 May 18;15:17562848221098246. doi: 10.1177/17562848221098246. eCollection 2022.
5
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.在前瞻性、观察性 CORRELATE 研究中，在常规临床实践中使用regorafenib 治疗转移性结直肠癌患者的安全性和有效性。
Eur J Cancer. 2019 Dec;123:146-154. doi: 10.1016/j.ejca.2019.09.015. Epub 2019 Nov 4.
6
F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12).F-FDG-PET/CT作为瑞戈非尼治疗转移性结直肠癌疗效的影像生物标志物（JACCRO CC-12）
Oncol Ther. 2021 Dec;9(2):635-645. doi: 10.1007/s40487-021-00173-1. Epub 2021 Oct 9.
7
Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.瑞戈非尼治疗难治性转移性结直肠癌：一项多中心回顾性研究
Front Oncol. 2022 Mar 30;12:838870. doi: 10.3389/fonc.2022.838870. eCollection 2022.
8
Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.瑞戈非尼用于转移性结直肠癌的真实世界治疗：单中心回顾
Curr Oncol. 2017 Aug;24(4):234-239. doi: 10.3747/co.24.3562. Epub 2017 Aug 31.
9
Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.瑞戈非尼在土耳其难治性转移性结直肠癌患者中的安全性和疗效：单臂、开放标签的REGARD研究。
BMJ Open. 2020 Mar 26;10(3):e027665. doi: 10.1136/bmjopen-2018-027665.
10
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.优化三线转移性结直肠癌患者使用替氟尿苷/替匹嘧啶和瑞戈非尼的治疗顺序。
Clin Colorectal Cancer. 2018 Dec;17(4):274-279. doi: 10.1016/j.clcc.2018.05.012. Epub 2018 Jun 8.

引用本文的文献

1
Optimizing Regorafenib Dosing and Patient Management in Colorectal Cancer in Latin America: Perspectives from Argentina.优化拉美结直肠癌患者的瑞戈非尼剂量和管理：来自阿根廷的观点。
Oncologist. 2021 Jun;26(6):e992-e995. doi: 10.1002/onco.13723. Epub 2021 Mar 6.

本文引用的文献

1
Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India.瑞戈非尼治疗多线治疗失败转移性结直肠癌的毒性反应和早期结局：来自印度一家三级癌症中心的经验。
Ann Transl Med. 2016 Feb;4(4):74. doi: 10.3978/j.issn.2305-5839.2016.02.05.
2
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 联合最佳支持治疗对比安慰剂联合最佳支持治疗用于既往治疗的转移性结直肠癌亚洲患者（CONCUR）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.
3
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.TAS-102 治疗难治性转移性结直肠癌的随机试验。
N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.
4
Regorafenib: start low and go slow.瑞戈非尼：起始剂量要低，增量要缓。
Target Oncol. 2015 Sep;10(3):445-7. doi: 10.1007/s11523-014-0352-7. Epub 2014 Dec 30.
5
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.FOLFIRI 联合西妥昔单抗与 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者（FIRE-3）：一项随机、开放标签、III 期临床试验。
Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.
6
Quality of life in the trastuzumab for gastric cancer trial.曲妥珠单抗治疗胃癌临床试验中的生活质量。
Oncologist. 2014 Jul;19(7):712-9. doi: 10.1634/theoncologist.2014-0058. Epub 2014 Jun 20.
7
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.帕尼单抗联合 FOLFOX4 治疗与结直肠癌的 RAS 突变。
N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
8
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.regorafenib 单药治疗既往治疗的转移性结直肠癌（CORRECT）：一项国际、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
9
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.ESMO 结肠癌和直肠癌患者管理共识指南。 个体化临床决策方法。
Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
10
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.多西他赛致严重中性粒细胞减少的药物人种学：已发表的 II 期和 III 期试验综合分析。
Int J Clin Oncol. 2013 Feb;18(1):96-104. doi: 10.1007/s10147-011-0349-5. Epub 2011 Nov 18.